Ärztliche Mitarbeiter

Direktion

Reinhardt, Prof. H. Christian

Univ.-Prof. Dr. med. Christian Reinhardt
Direktor der Klinik für Hämatologie und Stammzelltransplantation

  • 1996-2003
    Medical school, (Final grade: Sehr gut, highest honors), University of Hamburg, Germany; Humboldt University, Berlin, Germany; University  of Freiburg, Germany.

 

  • 1999-2003
    MD thesis, Department of Internal Medicine, Division 4, University of Freiburg. Entitled: Expression of functional CC- and CXC chemokine receptors in podocytes. Advisor: Prof. Dr. H. Pavenstädt (Grade: Summa cum laude, highest honors)
  • since 2020
    Professor for Hematology and Stem Cell Transplantation (W3), University Hospital Essen

  • since 2020
    Director Clinic for Hematology and Stem Cell Transplantation,University Hospital Essen

  • since 2020
    Elected member of the board of the Competence Network Malignant Lymphoma

  • since 2019
    Elected Vice-Speaker of the network of Mildred Scheel Schools of Oncology  (Hamburg, Würzburg, Dresden, Frankfurt, Köln-Bonn)

  • since 2019
    Co-Speaker Collaborative Research Center „Mechanisms of Drug Sensitivity and Resistance in Small Cell Lung Cancer“ (SFB-1399)

  • since 2018
    Speaker of the Mildred Scheel School of Oncology Cologne-Bonn: Cancer- and  Immuno-genomics

  • since 2017
    Speaker of the Else Kröner Research College: Clonal evolution in cancer

  • 2015-2020
    Attending physician at the Medical Clinic I of the University Hospital Cologne

  • 2015
    Board exam (certified in general internal medicine and hematology and medical  oncology)

  • 2015-2020
    Elected member of the executive board of the Center for Molecular Medicine Cologne

  • 2013-2019
    Head of the Clinical Research Unit-286 “Exploiting defects in the DNA damage response for the treatment of chronic lymphocytic leukemia”

  • 2012-2015
    Elected member of the steering committee of the Helmholtz Alliance Preclinical Comprehensive Cancer Center (PCCC) and scientific coordinator of Research Topic 3, Hematological Malignancies within the PCCC

  • 2012-2020
    Professor for Clinical and Molecular Oncology (W2), University Hospital Cologne

  • 2009-2015
    Emmy-Noether research group leader at the Max-Planck-Institute Cologne and the Medical Clinic I of the University Hospital Cologne

  • 2009
    Habilitation for Molecular Medicine at the Medical Faculty of the University of Cologne

  • 2004-2009
    Postdoctoral Associate, MIT, Department of Biology, Koch Institute, Advisors: Profs. M.B. Yaffe, MD, PhD and T. Jacks, PhD

  • 2004
    Postdoctoral Research Fellow, University of Münster, Germany, Advisor: Prof. Dr. H. Pavenstädt.

  • 2003
    Postdoctoral Research Fellow University of Freiburg, Germany,Advisor: Profs. Dr. G. Walz and Dr. T. Benzing

2017:  Gilead Research Award Oncology

2016:  Theodor Frerichs Award of the German Society for Internal Medicine

2012:  GlaxoSmithKline Research Award

2011:  Vincenz Czerny Award of the German Society for Hematology and Oncology

2011:  W2 Lichtenberg Professorship of the VolkswagenStiftung

2011:  CESAR Research Award of the Central European Society for Anticancer Drug Research

2011:  Johann-Georg-Zimmermann Award for Cancer Research

2010:  Young Leaders in Science Award of the Schering Stiftung

2009:  Emmy-Noether fellowship of the Deutsche Forschungsgemeinschaft

2009:  Startup grant from the Ministerium für Innovation, Wissenschaft, Forschung und Technologie des Landes NRW

2009:  NIH/NCI K99/R00 PI award (relinquished due to return to Germany)

2009:  Travel grant of the Deutsche Krebshilfe

2007:  MIT-Koch Award

2005:  Research fellowship of the Deutsche Forschungsgemeinschaft

2004:  Young investigator award of the Deutsche Nierenstiftung

  1. Deutsche Gesellschaft für Innere Medizin
  2. Deutsche Gesellschaft für Hämatologie und Onkologie
  3. Deutsche Krebsgesellschaft
  4. Deutsche Gesellschaft für DNA Reparaturforschung
  5. Deutscher Hochschulverband
  6. Kompetenznetz Maligne Lymphome
  7. German Lymphoma Alliance
  8. European Hematology Association
  9. American Association for Cancer Research
  10. European Association for Cancer Research
  11. European Society of Medical Oncology
  12. Central European Society for Anticancer Drug Research
  13. Gesellschaft für Versuchstierkunde / Society of Laboratory Animal Science (GV-SOLAS)
  14. Verband der Leitenden Krankenhausärzte
  1. Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun A, Ozretić L, Künstlinger H, Kambartel   K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D, Siedek F, Persigehl T, Mauch C, Bartkova J, Bradley A, Sprick MR, Trumpp A, Rad R, Saur D, Bartek J, Wolf J, Büttner R, Thomas RK, Reinhardt HC: A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer. Cell, 2015 Jul 2;162(1):146-59.

  2. Jachimowicz RD, Beleggia F, Isensee J, Bhavana VB, Goergens J, Bustos MA, Doll MA, Shenoy A, Checa-Rodriguez C, Wiederstein JL, Baranes-Bachar K, Bartenhagen C, Hertwig    F, Teper N, Nishi T, Schmitt A, Distelmaier F, Lüdecke HJ, Albrecht B, Krüger M, Schumacher  B, Geiger T, Hoon DSB, Huertas P, Fischer M, Hucho T, Peifer M, Ziv Y, Reinhardt HC*#, Wieczorek D*, Shiloh Y*: UBQLN4 represses homologous recombination and is overexpressed in aggressive tumors, Cell, 2019 Jan 24;176(3):505-519.e22, * Shared last   authors, # lead author contact

  3. Janes KA*, Reinhardt HC*, and Yaffe MB: Cytokine-induced signaling networks prioritize dynamic range over signal strength. Cell, 2008 Oct 17;135(2):343-54. *equal contribution

  4. Reinhardt HC, Aslanian AS, Lees JA, and Yaffe MB: p53 deficient cells rely on ATM and ATR-mediated checkpoint signaling through the p38 MAPK/MK2 pathway for survival after DNA damage. Cancer Cell, 2007 Feb;11(2):175-89.

  5. Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, Leeser U, van Oers J, Edelmann W, Heukamp LC, Reinhardt HC: A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discovery, 2014 May;4(5):592-605.

  6. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, Leenders F, Lu X, Fernandez-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan N, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub B, Becker C, Altmüller J, Yokota J, Khono T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Peterson I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion P, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell P, Solomon B, Koch I, Lindner M, Muscarella LA, La Torre A, Field JK, Jakopovic M, Knezevic J, Castanos-Velez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Bolting J, Sandlin M, Sanchez-Cespedes M, Salvesen H, Achter V, Lang U, Bogus M, Schneider P, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt HC, Perner S, Heukamp LC , Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK: Comprehensive genomic profiling of small cell lung cancer. Nature, 2015 Jul 13.

  7. Wilker EW, van Vugt MA, Artim SA, Huang PH, Petersen CP, Reinhardt HC, Feng Y, Sharp PA, Sonenberg N, White FM, Yaffe MB.: 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature. 2007 Mar 15;446(7133)

  8. Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M, Thomas RK, Kreuzer KA, Frenzel LP, Monfared P, Martins-Boucas JM, Chen S, Reinhardt HC: Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med, 2013 Jun 12;5(189):189ra78.

  9. Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt M, Wang X, Linding R, Ong SE, Weaver D, Carr SA, Yaffe MB. DNA Damage activates A Spatially Distinct Late Cytoplasmic Cell Cycle Checkpoint Network Controlled by MK2-mediated RNA Stabilization. Mol Cell, 2010, 40;1, 34-49, 2010 Oct 8

  10. Knittel G, Liedgens P, Korovkina D, Seeger JM, Al-Baldawi Y, Al-Maarri M, Fritz C, Vlantis K, Bezhanova S, Scheel AH, Wolz OO, Reimann M, Möller P, López C, Schlesner M, Lohneis P, Weber ANR, Trümper L, ICGC MMML-Seq Consortium, Staudt LM, Ortmann M, Pasparakis M, Siebert R, Schmitt CA, Klatt AR, Wunderlich FT, Schäfer SC, Persigehl T, Montesinos-Rongen M, Odenthal M, Büttner R, Frenzel LP, Kashkar H, Reinhardt HC: B cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B cell lymphoma in mice. Blood, 2016 Jun 2;127(22):2732-41.

Leitungsteam / Oberärzte und Bereichsleitung

PD Dr. med. Bastian von Tresckow

PD Dr. med. Bastian von Tresckow

Stellvertretender Direktor
Leiter Schwerpunkt Lymphome

PD Dr. med. Andreas Hüttmann

PD Dr. med. Andreas Hüttmann

Leitender Oberarzt
Ärztlicher Leiter hämatologische Abulanz Leiter Studienzentrale

Dr. med. Rudolf Trenschel

Dr. med. Rudolf Trenschel

Leitender Oberarzt
Leiter Stammzelltransplantation

Dr. med. Nina Steckel

Dr. med. Nina Steckel

Leitung Internistische Intensivmedizin
Personaloberärztin

PD Dr. med. Dr. phil. Lambros Kordelas

PD Dr. med. Dr. phil. Lambros Kordelas

Oberarzt
Finanzoberarzt

PD Dr. med. Maher Hanoun

PD Dr. med. Maher Hanoun

Geschäftsführender Oberarzt
Leiter Schwerpunkt akute Leukämien

Dr. med. Alexander Carpinteiro

Dr. med. Alexander Carpinteiro

Oberarzt
Leiter Schwerpunkt multiples Myelom, Amyloidose

PD Dr. med. Markus Ditschkowski

PD Dr. med. Markus Ditschkowski

Oberarzt
Leiter der KMT Ambulanz

PD Dr. med. Joachim Göthert

PD Dr. med. Joachim Göthert

Oberarzt
Leiter Schwerpunkt myeloproliferative Neoplasien

Dr. med. Vesna Klisanin

Dr. med. Vesna Klisanin

Leitung des Bereichs post-Allo-Transplant
Management
Stellv. Leitung KMT Ambulanz

Prof. Dr. med. Dipl.-Biol. Michael Koldehoff

Prof. Dr. med. Dipl.-Biol. Michael Koldehoff

Oberarzt
Leiter klinische Infektiologie

Dr. med. Richard Noppeney

Dr. med. Richard Noppeney

Oberarzt
Leiter Apherese und Herstellungsbereich

PD Dr. med. Jürgen Novotny

PD Dr. med. Jürgen Novotny

Oberarzt
Lehrbeauftragter

Prof. Dr. med. Alexander Röth

Prof. Dr. med. Alexander Röth

Oberarzt
Leiter Schwerpunkt nicht-maligne Hämatologie

Asterios Tzalavras

Oberarzt
Stellv. Leitung Internistische Intensivmedizin

Dr. med. Julia von Tresckow

Oberärztin
Leitung Schwerpunkt CLL, indolente Lymphome